Fas and Fas ligand gene polymorphisms in Turkish patients with Familial Mediterranean Fever

Emine Gulce Ozel1, Gulay Gulbol Duran1, Muhammet Murat Celik2

  • 1Department of Medical Biology, Faculty of Medicine, Mustafa Kemal University, 31100, Hatay, Turkey.

Gene
|April 27, 2017
PubMed

Insights

This study investigated genetic variations in Fas (FAS) and Fas ligand (FASLG) genes in Familial Mediterranean Fever (FMF) patients. While FASLG c.-844TC genotype may be protective, neither FAS nor FASLG polymorphisms were linked to FMF clinical features.

Area of Science:

  • Genetics
  • Immunology
  • Molecular Biology

Background:

  • Familial Mediterranean Fever (FMF) is an autoinflammatory disorder involving neutrophils.
  • Fas (FAS) and Fas ligand (FASLG) are crucial for apoptosis, particularly in neutrophils during inflammation.

Purpose of the Study:

  • To investigate the association between FAS c.-671A>G and FASLG c.-844C>T gene polymorphisms and FMF.
  • To determine if these polymorphisms correlate with the clinical manifestations of FMF.

Main Methods:

  • PCR-RFLP technique was used to analyze FAS and FASLG polymorphisms in 97 FMF patients and 70 healthy controls.
  • Genotype and allele frequencies, as well as haplotype frequencies, were compared between groups.

Main Results:

  • No significant difference in FAS c.-671A>G genotype or allele frequencies between FMF patients and controls.
  • A significant difference in FASLG c.-844TC genotype frequency was observed between FMF patients and controls.
  • No correlation found between studied polymorphisms and FMF clinical features (fever, arthritis, pain, erythema).

Conclusions:

  • FAS c.-671A>G and FASLG c.-844 allele are unlikely risk factors for FMF in the Turkish population.
  • FASLG c.-844TC genotype may offer protection against FMF.
  • Higher FASLG c.-844CC genotype frequency in FMF patients might suggest a role in delayed neutrophil apoptosis and inflammation, though not statistically significant.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
69
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53